Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes by Sayeeda, Afsar et al.
SAGE-Hindawi Access to Research
Autoimmune Diseases
Volume 2010, Article ID 174891, 5 pages
doi:10.4061/2010/174891
Clinical Study
Herpes Zoster Infectionsin SLE in a University Hospital in
Saudi Arabia: Risk Factors and Outcomes
AfsarSayeeda,HussainAlArfaj,NajmaKhalil, andA. S.AlArfaj
Division of Rheumatology, Department of Medicine, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461,
Riyadh, Saudi Arabia
Correspondence should be addressed to Afsar Sayeeda, afsarsayeeda@hotmail.com
Received 26 January 2010; Revised 1 June 2010; Accepted 19 August 2010
Academic Editor: Francesco Indiveri
Copyright © 2010 Afsar Sayeeda et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Patients with SLE carry an increased risk of infection that account for 11–23% of all hospitalized patients and 50% of all SLE
patients develop major infections during the course of their disease. Globally Herpes Zoster has been reported as the most
frequent viral infection in SLE patients. We determined the clinical spectrum, disease sequelae and the risk factors associated
with the development of Herpes Zoster in patients with SLE and their outcomes. Retrospective case control study of Herpes
Zoster infections was done in SLE patients between 1982 and 2006. Cases were matched 1:2 to controls for age, race, sex and
duration of follow up. Clinical features of the cases from the time of lupus diagnosis to the time of Zoster were compared to
their respective controls over similar time periods. Thirty two SLE cases were compared to sixty four controls. Cases were more
likely to have received cyclophosphamide (P = .0223) and intravenous methylprednisolone pulse therapy (P = .0026), MMF
(P<. 02), had leucopenia (P = .0407) and hemolytic anemia (P = .0344). More cases than controls had lupus nephritis, cerebritis,
thrombocytopenia but the diﬀerences did not reach statistical signiﬁcance. The mean oral prednisolone dose and proportion of
patients receiving immunosuppressives including pulse methylprednisolone therapy, IV Cyclophosphamide and mycophenolate
was signiﬁcantly higher in patients with active SLE compared to patients with SLE in remission at the time of Herpes Zoster
(P<. 05). Disseminated Zoster developed in patients with active SLE (7/9) compared to patients with SLE in remission (0/23).
None of the patients had postherpetic neuralgia or bacterial super infection. Immunosuppressive medications were discontinued
at the time of diagnosis of Zoster in 19 of 32 patients and all patients received antiviral medications.There were no permanent
neurologic deﬁcits or deaths. We conclude that Herpes Zoster infections occur at increased frequency among patients with SLE
and carry signiﬁcant morbidity. Immunosuppressive therapy and severe manifestations of lupus may be risk factors for the
development of Herpes Zoster although not necessarily at the time of disease ﬂare or immunosuppressive therapy. Our study
suggests that although Herpes Zoster occurs frequently in patients with SLE, it has a relatively benign course.
1.Introduction
Herpes Zoster, a painful vesicular eruption with a der-
matomal distribution, is caused by reactivation of a latent
Varicella Zoster virus infection [1]. It may be complicated by
bacterial superinfection and cutaneous and visceral dissem-
ination of lesions which may be life threatening. Although
it occurs most commonly in otherwise healthy elderly
individuals, immunocompromised patients (i.e., those with
malignancies especially lymphoproliferative diseases, organ
allograft, and autoimmune diseases such as SLE) appear
to be at a particular risk for both Herpes Zoster and its
complications [2–8]. Herpes Zoster in these patients has a
greater tendency to disseminate and to cause morbidity [9–
12].
Patients with SLE may be at increased risk for Zoster
infection by virtue of both the impairment in cell-mediated
immunity which characterizes the disease and by treatment
of severe disease with high dose corticosteroids or immuno-
suppressive agents. Indeed, several studies have reported an
increased incidence of Herpes Zoster in patients with SLE
[13–18].
T h e r eh a v eb e e nn os t u d i e si nt h eS a u d ip o p u l a t i o n
addressing the frequency or natural history of Herpes2 Autoimmune Diseases
Zoster infections in patients with SLE or the desirability of
withdrawing their immunosuppressive medications and or
instituting antiviral therapy.
In this paper retrospective case controlled study was
used to determine its frequency, assess speciﬁc risk factors,
its association with SLE disease manifestations, and their
treatment, and deﬁnes prognostic indicators for serious
complications of Herpes Zoster.
2.MaterialsandMethods
2.1. Patients. SLE patients deﬁned by the ACR 1982 revised
criteria seen at the outpatient and inpatient facilities
of the university hospital that developed Herpes Zoster
were considered for the period extending from 1982 to
2006. Medical records of patients with Herpes Zoster were
reviewed to verify the diagnosis and to determine its
treatment and outcome as well as the activity of SLE at
the time of infection. Patients with Herpes Zoster but with
other systemic rheumatic diseases for example, rheumatoid
arthritis, dermatomyositis,overlapsyndrome,andWegener’s
granulomatosis were excluded from this study.
2.2. Case Deﬁnition and Assessment of Disease. A case was
deﬁnedasapatientwithSLElivingordeceasedwithahistory
of a characteristic vesicular rash in a dermatomal distri-
bution. Herpes Zoster was considered to be disseminated
when the dermatomal pattern was followed by progressive
widespread vesicular lesions. Post herpetic neuralgia was
deﬁnedaspainpersistingmorethan1monthafterresolution
of cutaneous lesions.
For the purposes of this study, we included as cases
only those patients with a history of Herpes Zoster anytime
after the ﬁrst physician diagnosis of SLE. The diagnosis of
Herpes Zoster was made from the history and the docu-
mentation of a characteristic rash with associated symptoms
in a dermatomal distribution leaving little doubt as to the
diagnosis. Viral isolation by culture or serology was not done
for conﬁrmation of Herpes Zoster.
A control was deﬁned as a patient with SLE with no
history of Herpes Zoster. Cases and controls were matched
1:2 by age, race, gender, and SLE disease duration (from
diagnosis to the time of review), clinical manifestations, and
treatment of SLE (use of high dose steroid (1mg/kg/day)
& other immunosuppressive agents) in the three months
preceding and the three months following the Herpes Zoster
episode. Initial disease activity was assessed by the SLE
Disease Activity Index score, which is a validated measure of
disease activity for patients with SLE [19].
Cumulative clinical manifestations of disease and its
treatmentwerecomparedbetweenpatientswithandwithout
Herpes Zoster to determine its risk factors. Events were
analyzed up to and including the time of the ﬁrst Herpes
Zoster episode in the infected group and to date of the
last followup in the uninfected group, to compare disease
features during the period when the patients were at risk of
ﬁrst Zoster episode.
Risk factors were deﬁned by the ever use and dose
of prednisolone, use of an immunosuppressive medication,
lupusnephritis.Thepresenceofthesepotentialriskfactorsin
cases was determined from the time of SLE diagnosis to the
time of Herpes Zoster infection and in controls over similar
time periods.
2.3. Statistical Analysis. Data were analyzed by SPSS version
12 and the results are presented as percentages and means.
Comparison of variables was carried out using chi-square
test or Fisher’s exact test when appropriate. Statistical
signiﬁcance was deﬁned as P<. 05.
3. Results
A total of 32 cases of Herpes Zoster infection were identiﬁed
among 624 SLE patients which gives a prevalence of 5.1%
of Herpes Zoster infections in SLE. The demographic and
clinical features as well as therapy in 32 Herpes Zoster SLE
patients were compared with 64 non-Herpes Zoster SLE
patients (patients: controls in ratio of 1:2) as shown in
Table 1.
Table 1 shows that 30 (93.8%) of Herpes Zoster patients
were female and 2 (6.3%) were male. Their mean age was
31.4±11.4 years (range 11–60 years) and the mean duration
of SLE was 8.6 ± 6.0 years (range 2–22 years). Of them, 30
were Arabs (Saudi and non-Saudi), 1 was Indian, and 1 was
Pakistani. The disease was more active in our cases with a
mean SLEDAI = 20.7 ± 9.8 (range 2–36) when compared to
controls mean SLEDAI = 12.6 ±5.2 (range 2–29) P<. 0001.
Regarding the disease manifestations, it was found
that nephritis occurred in 18 (56.3%), cerebritis in 2
(6.3%), serositis in 9 (28.1%), leucopenia in 17 (53.1%),
thrombocytopenia in 8 (25.0%), and hemolytic anemia in
11 (34.4%) patients. All the 32 patients (100%) received
oral prednisolone (PSL), 14 (43.8%) received intravenous
cyclophosphamide (Cyclo IV), 16 (50.0%) pulse methyl-
prednisolone (MPSL), 14 (43.8%) azathioprine (AZA), and
6 (18.8%) mycophenolate mofetil (MMF). The mean daily
dose of oral PSL was 21.9±27.7mg (range 5–100mg). Cyclo
IV was given in 12 doses as 10mg/Kg in 18 months. The
mean daily dose of AZA was 125.0 ± 25.0mg (range 100–
150mg) and of MMF was 1.1 ±1.1gm (range 0.5–3gm).
The female to male ratio and racial background were
similar in the two groups. Herpes Zoster SLE cases were
signiﬁcantly more likely to have had leucopenia (P =
.04) and hemolytic anemia (P = .03) compared to non-
Herpes Zoster SLE controls. Although the other serious
manifestations including nephritis, cerebritis, serositis, and
thrombocytopenia were more frequent in cases compared to
controls, the diﬀerences did not reach statistical signiﬁcance
(P>. 05). Immunosuppressives, in particular Cyclophos-
phamide IV (P = .0223) and pulse methylprednisolone
(MPSL) (P = .0026), were more frequently prescribed to
Herpes Zoster SLE patients compared to non-Herpes Zoster
SLE patients.
Herpes Zoster lesions were disseminated in 7 (21.9%)
of the 32 patients and localized in 25 (78.1%). Treatment
of Herpes Zoster infection comprised of antiviral therapyAutoimmune Diseases 3
Table 1: Comparison of demographic and clinical features in SLE Zoster and SLE Non-Zoster patients.
Characteristics Cases Controls P value
SLE with Zoster
(n = 32) N (%)
SLE without Zoster
(n = 64) N (%)
Sex
Male 2 (6.3) 4 (6.3)
Female 30 (93.8) 60 (93.8)
Race .7656
Arabs 30 (93.8) 61 (95.3)
Non Arabs 2 (6.3) 3 (4.7)
Nephritis 18 (56.3) 28 (43.8) .2474
Cerebritis 2 (6.3) 2 (3.1) .5075
Serositis 9 (28.1) 13 (20.3) .4089
Leucopenia 17 (53.1) 20 (31.2) .0407
∗
Thrombocytopenia 8 (25.0) 11 (17.2) .3879
Hemolytic anemia 11 (34.4) 9 (14.1) .0344
∗
Cyclo IV 14 (43.8) 13 (20.3) .0223
∗
MPSL 16 (50.0) 12 (18.8) .0026
∗
Azathioprine 14 (43.8) 20 (31.2) .2336
MMF 6 (18.8) 6 (9.4) .2318
∗signiﬁcant (P<. 05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, MMF: mycophenolate mofetil.
acyclovir that was administered to 19 (59.5%) patients in
oral form and to 13 (40.5%) patients intravenously. SLE was
active at the time of Herpes Zoster infection in 9 (28.1%)
and in remission in 23 (71.9%) patients. The duration
of SLE remission ranged from 2 months to 4 years. SLE
did not ﬂare up in response to Herpes Zoster infection.
Immunosuppressives were continued in 13 (40.6%) and
discontinued in 19 (59.4%) patients.
Results of SLE treatment regimens at the time of Zoster
in relation to disease activity are presented in Table 2.T h e
mean oral PSL dose and proportion of patients receiving
immunosuppressives including pulse MPSL, cyclo IV, and
MMF was signiﬁcantly higher in patients with active SLE
compared to patients with SLE in remission at the time of
Zoster (P<. 05).
Disseminated Zoster developed in patients with active
SLE(7/9)comparedtopatientswithSLEinremission(0/23).
This explains the results in Table 3 that those who developed
disseminated Herpes Zoster had received signiﬁcantly more
immunosuppresssives than those who developed localized
Herpes Zoster (P<. 05).
4. Discussion
Herpes Zoster reactivation of the Varicella Zoster virus
(VZV) occurs in 10%–20% of population over a lifetime
[2, 20]. The annual incidence of Herpes Zoster is less than
0.5% in the general population. Herpes Zoster occurs in
patients with SLE much more commonly than generally
expected [14].
Immunological studies on patients with SLE showed
that there are basic defects present in the disease itself (i.e.,
impaired cell-mediated immunity, defective delayed hyper-
sensitivity reaction and a hyperactive humoral immunity).
The eﬀects of medication (high dose corticosteroids and
immunosuppressive agents or both) used to treat severe
disease may further lead to a reduction in the host resistance
to infections [21–25].
The predisposing risk factors and the nature of compli-
cations in SLE patients vary signiﬁcantly among diﬀerent
ethnic and geographical groups. Japanese patients with SLE
seem to be much more susceptible to Herpes Zoster with
an incidence of 43% [13, 14], the reported prevalence in
diﬀerent series varying from 13.5% to 46.6% of adult SLE
patients. This is much higher than what we found in our
population of patients with SLE, the prevalence rate for
Herpes Zoster being 6% and by Al-Rayes et al. 5% [26].
Patients who had Herpes Zoster also experienced more
episodes of major infections during their disease course [27].
This could be due to disease activity, immunosuppressive
therapy and host genetic factors that determine the general
susceptibility to both infections and SLE. T cell function
plays an important role in maintaining VZV latency in the
host. In this study, two thirds of the patients had heightened
lupus activity within the 6-month period before Herpes
Zoster either because of disease onset or ﬂare up.
Herpes Zoster lesions were localized in 25% of our
patients. The incidence of patients with dissemination in
our study was much higher (21.9%) compared to the other
studies which ranged from 2%–11% [28, 29]. The reason
may be that this is more common among patients receiving
high-dose steroids and immunosuppressives [29]o rd u et o
a delay in instituting antiviral therapy. The mean dose of
oral prednisolone in our SLE cases at the time of Herpes
Zosterwas80mgcomparedto12mgincontrols.Areduction
in the dose of steroids should be strongly considered in4 Autoimmune Diseases
Table 2: SLE treatment at the time of Zoster infection in relation to SLE activity.
SLE treatment Active SLE(n = 9) N (%) SLE in remission (n = 23) N (%) P value
MPSL 3 (88.9) 8 (34.7) .0007
∗
Cyclo IV 7 (77.8) 7 (30.4) .0086
∗
AZA 6 (66.7) 8 (34.8) .0964
∗
MMF 6 (66.7) 0 (0.0) .0002
∗
∗signiﬁcant (P<. 05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate, mofetil Oral PSL:
(Oral prednisolone).
(All patients (100%) received oral prednisolone. The mean dose in active SLE cases was 80 ±3mg and in patients with SLE in remission was 12.2 ±1mg).
Table 3: Disseminated/Localized Zoster in relation to SLE treatment.
SLE Therapy Disseminated (n = 7) Localized (n = 25) P value
N (%) N (%)
MPSL 6 (85.7) 10 (40.0) .0094
∗
Cyclo IV 6 (85.7) 8 (32.0) .0024
∗
AZA 5 (71.4) 9 (36.0) .0808
∗
MMF 6 (85.7) 0.0 (0.0) .0000
∗
∗signiﬁcant (P<. 05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate mofetil.
patients receiving high-dose prednisolone at the onset of
Zoster episode.
All our Herpes Zoster patients had uneventful recovery.
Two patients had multiple episodes (2 each), and three
of them had Herpes Zoster opthalmicus, none of them
had clinically apparent CNS or visceral involvement or
other complications such as permanent motor deﬁcits,
pneumonia, cutaneous scarring, regardless of treatment, or
continuation of immunosuppressive medications. None of
our patients had post herpetic neuralgia. No patient had
bacterial superinfection and there were no deaths. Herpes
Zoster in our SLE patients was relatively mild and is similar
to that reported by Moutsopoulos et al. in his series [15].
All our patients received antiviral therapy either in the
oral or IV form. Immunosuppressives were discontinued
in 59% of our patients but given the duration of action
of immunosuppressant agents, altering their regimen will
probably be of no beneﬁt [28].
In our series and in the series of Khal et al., patients
who developed Zoster were more likely to have experienced
serious manifestation of SLE, including nephritis, hemolysis,
and thrombocytopenia and to have required treatment with
cyclophosphamide. In addition, our patients had received
intravenous methylprednisolone therapy. The retrospective
natureofthestudymayhaveledustomissepisodesofZoster
among patients with less serious SLE who might either have
had less frequent routine visits or have been less likely to seek
medical attention for their Zoster. Moreover, two thirds of
our patients had no major SLE organ involvement and were
receiving neither high dose steroids nor immunosuprressive
therapyinthethreemonthspriortoandincludingtheZoster
episodebutstillsoughtmedicalattention.ManyoftheZoster
reactivations in both these series occurred when SLE was
inactive.
SimilarresultswereshownbyManzietal.whoalsonoted
that the patients who developed Zoster had more severe
SLE [16]. They also found immunosuppressive therapy to
be a risk factor for the development of Herpes Zoster
infections in these patients. Whether immunosuppressive
therapy acts as a marker for lupus activity which may
be an independent risk factor for Herpes Zoster could
not be ascertained from their study. Both bacterial and
viral infections have been associated with overall disease




frequency among patients with SLE and have a relatively
benign course. Herpes Zoster infections in patients with
lupus are not necessarily associated with excessive morbid-
ity; discontinuing needed immunosuppressive therapy in
patients with SLE may be unnecessary in the setting of
Zoster infection. Herpes Zoster SLE cases were signiﬁcantly
more likely to have had serious disease manifestations. The
mean oral PSL dose and proportion of patients receiving
immunosuppressive including pulse PSL, cyclo IV, and
mycophenolate was signiﬁcantly higher in patients with
active SLE compared to patients with SLE in remission at the
time of Zoster (P<. 05). Disseminated Zoster developed in
patients with active SLE (7/9) compared to patients with SLE
in remission (0/23).
Observations by various other authors along with our
own suggest that the primary risk for Zoster in patients with
SLE is the basic immunologic imbalance intrinsic to lupus,
rather than some distinctive immunologic abnormality
associated with disease ﬂares or their treatment. Aggressive
treatmentregimensforlupus,incontrast,areassociatedwith
the risk for potentially serious complications of Zoster and
patients receiving such regimens should be managed with
increased clinical vigilance.Autoimmune Diseases 5
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